Literature DB >> 11000521

Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.

A M Hennige1, R Lammers, D Arlt, W Höppner, V Strack, G Niederfellner, F J Seif, H U Häring, M Kellerer.   

Abstract

Multiple endocrine neoplasia 2A (MEN 2A) is an inherited disease caused by mutations of the Ret proto-oncogene. Although many different Ret mutations have been described, little is known about the signaling pathways triggered by the Ret oncogene. In this study, we have determined the signaling properties of a Ret-9bp duplication encoding amino acids 634-636, which was recently identified in a patient with all clinical features of the MEN 2A syndrome. The Ret-9bp duplication leads to constitutive activation of the Ret tyrosine kinase. Furthermore, Ret-9bp increased mitogenic and transforming activity demonstrated by thymidine incorporation as well as colony formation in soft agar. Studying intracellular signaling pathways, which may be involved in malignant transformation of Ret-9bp expressing NIH3T3 cells, we could demonstrate Ret-9bp dependent phosphorylation of insulin receptor substrate-2 (IRS-2) with consecutive activation of phosphatidylinositol 3-kinase (PI 3-kinase) and protein kinase B (PKB/AKT). Moreover, Ret-9bp induces phosphorylation of SHC resulting in growth factor receptor binding protein-2 (Grb-2) binding and activation of the mitogen activating protein (MAP) kinase pathway. In addition to these postreceptor cytoplasmic signaling events, we have studied nuclear signal by Ret-9bp and found activation of c-jun and jun-D, two members of the jun/AP-1 family of transcription factors. In summary, an oncogenic 9bp duplication of Ret causes Ret dimer formation and ligand independent activation of the tyrosine kinase. Besides the signaling steps leading to MAPK activation, we could demonstrate that Ret-9bp induced constitutive activation of a signaling pathway involving IRS-2, PI 3-kinase and PKB/AKT which could transduce the oncogenic Ret signal to increased gene transcription via activation of the jun/AP-1 transcription factor family.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11000521     DOI: 10.1016/s0303-7207(00)00283-5

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  9 in total

1.  The PTB domain of ShcA couples receptor activation to the cytoskeletal regulator IQGAP1.

Authors:  Matthew J Smith; W Rod Hardy; Guang-Yao Li; Marilyn Goudreault; Steven Hersch; Pavel Metalnikov; Andrei Starostine; Tony Pawson; Mitsuhiko Ikura
Journal:  EMBO J       Date:  2010-01-14       Impact factor: 11.598

2.  Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2.

Authors:  Robert K Dearth; Xiaojiang Cui; Hyun-Jung Kim; Isere Kuiatse; Nicole A Lawrence; Xiaomei Zhang; Jana Divisova; Ora L Britton; Syed Mohsin; D Craig Allred; Darryl L Hadsell; Adrian V Lee
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

3.  Plzf regulates germline progenitor self-renewal by opposing mTORC1.

Authors:  Robin M Hobbs; Marco Seandel; Ilaria Falciatori; Shahin Rafii; Pier Paolo Pandolfi
Journal:  Cell       Date:  2010-08-06       Impact factor: 41.582

4.  Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer.

Authors:  V Vasko; M Saji; E Hardy; M Kruhlak; A Larin; V Savchenko; M Miyakawa; O Isozaki; H Murakami; T Tsushima; K D Burman; C De Micco; M D Ringel
Journal:  J Med Genet       Date:  2004-03       Impact factor: 6.318

5.  Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies.

Authors:  Karen Gómez; Jeena Varghese; Camilo Jiménez
Journal:  J Thyroid Res       Date:  2011-05-16

Review 6.  The Novel Functions of High-Molecular-Mass Complexes Containing Insulin Receptor Substrates in Mediation and Modulation of Insulin-Like Activities: Emerging Concept of Diverse Functions by IRS-Associated Proteins.

Authors:  Fumihiko Hakuno; Toshiaki Fukushima; Yosuke Yoneyama; Hiroyasu Kamei; Atsufumi Ozoe; Hidehito Yoshihara; Daisuke Yamanaka; Takashi Shibano; Meri Sone-Yonezawa; Bu-Chin Yu; Kazuhiro Chida; Shin-Ichiro Takahashi
Journal:  Front Endocrinol (Lausanne)       Date:  2015-05-26       Impact factor: 5.555

Review 7.  Selective use of vandetanib in the treatment of thyroid cancer.

Authors:  Poupak Fallahi; Flavia Di Bari; Silvia Martina Ferrari; Roberto Spisni; Gabriele Materazzi; Paolo Miccoli; Salvatore Benvenga; Alessandro Antonelli
Journal:  Drug Des Devel Ther       Date:  2015-07-03       Impact factor: 4.162

8.  IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer.

Authors:  Elizabeth Day; George Poulogiannis; Frank McCaughan; Shani Mulholland; Mark J Arends; Ashraf E K Ibrahim; Paul H Dear
Journal:  Int J Exp Pathol       Date:  2013-04-18       Impact factor: 1.925

Review 9.  The Hirschsprung's-multiple endocrine neoplasia connection.

Authors:  Sam W Moore; Monique Zaahl
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.